Robert Kilkuskie
Director/Board Member at Michigan High Throughput Screening Center
Robert Kilkuskie active positions
Companies | Position | Start | End |
---|---|---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Director/Board Member | - | - |
National Institute of Health Policy | Corporate Officer/Principal | 30/04/2010 | - |
Career history of Robert Kilkuskie
Statistics
International
United States | 3 |
Operational
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Commercial Services |
National Institute of Health Policy |
- Stock Market
- Insiders
- Robert Kilkuskie
- Experience